Benchmark Maintains Buy on AbCellera Biologics, Lowers Price Target to $12
Portfolio Pulse from richadhand@benzinga.com
Benchmark analyst Robert Wasserman maintains a Buy rating on AbCellera Biologics (NASDAQ:ABCL) but lowers the price target from $20 to $12.
August 31, 2023 | 12:37 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Benchmark analyst maintains a Buy rating on AbCellera Biologics but lowers the price target from $20 to $12.
The news is directly related to AbCellera Biologics. While the maintained Buy rating is positive, the lowered price target could have a negative impact. The net effect on the stock price in the short term is uncertain, hence the neutral score.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100